Sandoz Global Press Releases and News The latest news from Sandoz International. EGA becomes Medicines for Europe http://www.sandoz.com/media_center/press_releases_news/global_news/2016-03-10-ega-becomes-medicines-for-europe.shtml Sandoz proud to announce first Novartis Access treatments to Kenya http://www.sandoz.com/media_center/press_releases_news/global_news/2016-03-01-sandoz-medicines-play-a-lead-role-in-delivery-of-first-novartis-access-treatments-to-kenya.shtml Sandoz receives positive CHMP opinion for s.c. route of administration in biosimilar Binocrit’s® nephrology indication http://www.sandoz.com/media_center/press_releases_news/global_news/2016-02-29-sandoz-receives-positive-chmp-opinion-for-binocrit.shtml Sandoz teams up with World Child Cancer to "even the odds" for children worldwide http://www.sandoz.com/media_center/press_releases_news/global_news/2016-02-15-sandoz-teams-up-with-world-childhood-cancer.shtml Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer’s biosimilar infliximab in EEA http://www.sandoz.com/media_center/press_releases_news/global_news/2016-02-12_sandoz-strengthens-biosimilars-portfolio-acquisition-infliximab-in-eea.shtml Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim http://www.sandoz.com/media_center/press_releases_news/global_news/2016-02-11_ema-acceptance-pegfilgrastim.shtml Sandoz’s Carol Lynch elected as chair of EGA’s European biosimilars group http://www.sandoz.com/media_center/press_releases_news/global_news/2016-02-09_ega-european-biosimilars-group.shtml Novartis Annual Results 2015 http://www.sandoz.com/media_center/press_releases_news/global_news/2016-01-27-full-year-results-2015.shtml Sandoz licenses its biosimilar rituximab to Kyowa Hakko Kirin in Japan http://www.sandoz.com/media_center/press_releases_news/global_news/2016-01-25-khk-japan.shtml Novartis moves to address superbug threat http://www.sandoz.com/media_center/press_releases_news/global_news/2016-01-21-novartis-antimicrobial-resistance.shtml Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept http://www.sandoz.com/media_center/press_releases_news/global_news/2015-12-08-acceptance-of-regulatory-submission-for-biosimilar-etanercept.shtml Phase III data shows Sandoz’ proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product http://www.sandoz.com/media_center/press_releases_news/global_news/2015-12-07-pegfilgrastim-has-similar-safety-and-efficacy-as-the-reference-product.shtml RICHARD FRANCIS ADDRESSES BIOSIMILARS AND MARKET ACCESS IN GUANDONG, CHINA http://www.sandoz.com/media_center/press_releases_news/global_news/2015-11-20-richard-francis_addresses-biosimilars-and-market-access-in-guandong-china.shtml Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by the FDA http://www.sandoz.com/media_center/press_releases_news/global_news/2015-11-18-regulatory-submission-for-biosimilar-pegfilgrastim-accepted-by-the-fda.shtml Generic medicines saved US healthcare system more than USD 250 billion in 2014 alone http://www.sandoz.com/media_center/press_releases_news/global_news/2015-11-05-generic-medicines-saved-us-healthcare-system-more-than-usd-250-billion-in-2014-alone.shtml Novartis Q3 Results 2015 http://www.sandoz.com/media_center/press_releases_news/global_news/2015_10_27_novartis_q3_2015_financial_results.shtml Sandoz introduces authorized generic version of LESCOL® XL in the US http://www.sandoz.com/media_center/press_releases_news/global_news/2015-10-19-sandoz-introduces-authorized-generic-version-of-lescol-xl-in-the-us.shtml Kenya is first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases http://www.sandoz.com/media_center/press_releases_news/global_news/2015-10-15-kenya-first-country-to-launch-novartis-access.shtml Sandoz is a triple winner at 2015 Global Generics & Biosimilars Awards in Madrid http://www.sandoz.com/media_center/press_releases_news/global_news/2015-10-14-sandoz-double-winner-at-biosimilars-awards-in-madrid.shtml FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept http://www.sandoz.com/media_center/press_releases_news/global_news/2015-10-02-fda-accepts-sandoz-regulatory-submission-for-a-proposed-biosimilar-etanercept.shtml Novartis launches ‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries http://www.sandoz.com/media_center/press_releases_news/global_news/2015-09-24-novartis-launches-novartis-access.shtml Sandoz Inaugurates BioInject – a new state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria http://www.sandoz.com/media_center/press_releases_news/global_news/2015-09-17-sandoz-inaugurates-bioinject.shtml Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States http://www.sandoz.com/media_center/press_releases_news/global_news/2015-09-03-sandoz-launches-zarxiotm-the-first-biosimilar-in-the-united-states.shtml Sandoz launches generic version of Pulmicort Respules® http://www.sandoz.com/media_center/press_releases_news/global_news/2015-07-28-sandoz-launches-generic-version-of-pulmicort-respules.shtml Sandoz launches Breathe Africa program to improve asthma diagnosis, treatment and patient outcomes in Zambia http://www.sandoz.com/media_center/press_releases_news/global_news/2015-07-23-sandoz-launches-breathe-africa-program-to-improve-asthma-diagnosis-treatment-and-patient-outcomes-in-zambia.shtml Court ruling paves the way for launch of Sandoz’s Zarxio as first US biosimilar http://www.sandoz.com/media_center/press_releases_news/global_news/2015-07-22-court-ruling-paves-the-way-for-launch-of-sandozs-zarxio-as-first-us-biosimilar.shtml Novartis announces second quarter results http://www.sandoz.com/media_center/press_releases_news/global_news/2015_07_21_novartis_q2_2015_financial_results.shtml Sandoz launches the Balans programme in Central and Eastern Europe to promote healthier living http://www.sandoz.com/media_center/press_releases_news/global_news/2015_07_09-sandoz-launches-the-balans-programme-in-central-and-eastern-europe.shtml Novartis introduces Declaration for Patients http://www.sandoz.com/media_center/press_releases_news/global_news/2015_06_30_novartis-introduces-declaration-for-patients.shtml Sandoz launches three new products in Japan http://www.sandoz.com/media_center/press_releases_news/global_news/2015_06_25_sandoz-launches-three-new-products-in-japan.shtml Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg http://www.sandoz.com/media_center/press_releases_news/global_news/2015_06_18_sandoz-announces-us-launch-of-Glatopa-the-first-generic-competitor-to-copaxone.shtml Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day http://www.sandoz.com/media_center/press_releases_news/global_news/2015_06_18_novartis_highlights_strong_innovation_momentum.shtml Delivering health equality and sustainable access to medicines for patients in Europe and worldwide http://www.sandoz.com/media_center/press_releases_news/global_news/2015_10_06_EGA_annual_conference_berlin.shtml Sandoz launches generic version of INTUNIV® extended release tablets in the US http://www.sandoz.com/media_center/press_releases_news/global_news/2015_06_04_sandoz_launches_generic_version_of_intuniv_extended_release_tablets.shtml Sandoz Poland celebrates the opening of a new packaging plant in Stryków http://www.sandoz.com/media_center/press_releases_news/global_news/2015_05_07_Sandoz_Poland_opening_packaging_plant.shtml Novartis Q1 Results 2015 http://www.sandoz.com/media_center/press_releases_news/global_news/2015_04_23_Novartis_Q1_2015_financial_results.shtml Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg http://www.sandoz.com/media_center/press_releases_news/global_news/2015_04_17_Sandoz_receives_FDA_approval_for_Glatopa_as_the_first_generic_competitor_to_MS_therapy_Copaxone_20_mg.shtml Innovative respiratory inhaler Airflusal® Forspiro® receives Alufoil Trophy 2015 http://www.sandoz.com/media_center/press_releases_news/global_news/2015_04_15_Innovative_respiratory_inhaler_Airflusal_Forspiro_receives_Alufoil_Trophy_2015.shtml Sandoz launches authorized generic version of EXFORGE® in the US http://www.sandoz.com/media_center/press_releases_news/global_news/2015_03_31_Sandoz_launches_authorized_generic_version_of_EXFORGE_in_the_US.shtml Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland http://www.sandoz.com/media_center/press_releases_news/global_news/2015_03_11_Sandoz_launches_innovative_respiratory_inhaler_AirFluSal_Forspiro_Portugal_Ireland.shtml FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz http://www.sandoz.com/media_center/press_releases_news/global_news/2015_03_06_fda_approves_first_biosimilar_zarxio_from_sandoz.shtml Novartis announces completion of transactions with GSK http://www.sandoz.com/media_center/press_releases_news/global_news/2015_03_02_Novartis_announces_completion_of_transactions_with_GSK.shtml Sandoz announces training program for midwives in Ethiopia, to reduce maternal and newborn mortality http://www.sandoz.com/media_center/press_releases_news/global_news/2015_03_02_Ethiopia_to_reduce_maternal_and_newborn_mortality.shtml On World Cancer Day, Sandoz highlights global problem of child cancer http://www.sandoz.com/media_center/press_releases_news/global_news/2015_02_04_World_Cancer_Day_Sandoz_highlights_global_problem_of_child_cancer.shtml Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses http://www.sandoz.com/media_center/press_releases_news/global_news/2015_01_27_Novartis_Q4_2014_financial_results.shtml Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee http://www.sandoz.com/media_center/press_releases_news/global_news/2014_01_07_Sandoz_biosimilar_filgrastim_recommended_for_approval_by_FDA_Oncologic_Drugs_Advisory_Committee.shtml Sandoz launches authorized generic version of Vivelle-Dot® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_12_22_Sandoz_launches_authorized_generic_version_of_Vivelle-Dot.shtml Sandoz Brazil launches Tadalafil, first generic version of Cialis® to treat erectile dysfunction http://www.sandoz.com/media_center/press_releases_news/global_news/2014_12_18_Sandoz_Brazil_launches_Tadalafil_first_generic_version_of_Cialis_to_treat_erectile_dysfunction.shtml Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_11_19_Phase-III-data-shows-Sandoz-investigational-biosimilar-filgrastim-has-similar-safety-and-efficacy-as-Amgen-NEUPOGEN.shtml Sandoz receives approvals in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_11_19_Sandoz_receives_approvals_in_Ireland_and_Czech_Republic_for_innovative_respiratory_inhaler_AirFluSal_Forspiro.shtml Sandoz launches ready-to-use oral formulation of ACC® cough medicine in Ukraine http://www.sandoz.com/media_center/press_releases_news/global_news/2014_11_12_Sandoz_launches_oral_formulation_ACC_cough_medicine_Ukraine.shtml Sandoz launches first generic version of cyclophosphamide injection, USP http://www.sandoz.com/media_center/press_releases_news/global_news/2014_11_10_sandoz_launches_first_generic_version_of_cyclophosphamide_injection_usp.shtml Sandoz receives approvals in Baltics for innovative respiratory inhaler AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_11_05_Sandoz_receives_approvals_in_Baltics_for_innovative_respiratory_inhaler_AirFluSal_Forspiro.shtml RAND projects $44.2 billion reduction in U.S. spend on biologics over the next decade from introduction of biosimilars http://www.sandoz.com/media_center/press_releases_news/global_news/2014_11_04_RAND_biosimilars_study.shtml EGA and EBG welcome a new milestone in the EU Biosimilars medicines regulatory framework http://www.sandoz.com/media_center/press_releases_news/global_news/2014_10_30_EGA_EBG_new_milestone_EU_Biosimilars.shtml Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter http://www.sandoz.com/media_center/press_releases_news/global_news/2014_10_28_Novartis_Q3_2014_financial_results.shtml Following commitment to United Nations’ Every Newborn Action Plan, Sandoz supplies life-saving antibiotic to combat child mortality http://www.sandoz.com/media_center/press_releases_news/global_news/2014_10_23_Sandoz_supplies_life_saving_antibiotic_to_combat_child_mortality.shtml Sandoz' Mark McCamish discusses US Biosimilars landscape on Biocentury TV http://www.sandoz.com/media_center/press_releases_news/global_news/2014_10_14_Sandoz_Mark_McCamish_discusses_US_Biosimilars_on_Biocentury_TV.shtml Sandoz wins Generics Bulletin 'Biosimilars Initiative of the Year' award http://www.sandoz.com/media_center/press_releases_news/global_news/2014_10_13_Sandoz_receives_generics_bulletin_award.shtml Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_10_09_Sandoz_receives_approval_in_Portugal_for_AirFluSal_Forspiro.shtml US celebrates 30 years of rapid generics growth http://www.sandoz.com/media_center/press_releases_news/global_news/2014_09_29_US_celebrates_30_years_of_rapid_generics_growth.shtml Sandoz contributes to fighting the number one cause of death globally http://www.sandoz.com/media_center/press_releases_news/global_news/2014_09_29_Sandoz_contributes_to_fighting_the_number_one_cause_of_death_globally.shtml Sandoz launches KERYDIN TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc. http://www.sandoz.com/media_center/press_releases_news/global_news/2014_09_23_kerydin.shtml Generic medicines saved US healthcare system nearly USD 240 billion in 2013 http://www.sandoz.com/media_center/press_releases_news/global_news/2014_09_16_generic_medicines.shtml Sandoz Regional BioCamp winner finishes among top three in Basel http://www.sandoz.com/media_center/press_releases_news/global_news/2014_09_01_sandoz_regional_biocamp.shtml Sandoz donates 25,000 units of benzathine penicillin to rheumatic heart disease study in Zambia http://www.sandoz.com/media_center/press_releases_news/global_news/2014_08_29_global_news.shtml Sandoz Brazil introduces a new option for oncology patients http://www.sandoz.com/media_center/press_releases_news/global_news/2014_08_26_Sandoz_Brazil_bortezomibe.shtml Sandoz receives first approval in Latin America for innovative respiratory inhaler Airflusal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_08_19_Sandoz_Airflusal_LATAM.shtml Sandoz Germany launches innovative new topical therapy for erectile dysfunction, a leading urological disorder http://www.sandoz.com/media_center/press_releases_news/global_news/2014_08_18_sandoz_germany_launches_innovative_new_topical_therapy_for_erectile_dysfunction.shtml Sandoz Sweden launches innovative new topical therapy for erectile dysfunction, a leading urological disorder http://www.sandoz.com/media_center/press_releases_news/global_news/2014_08_04_vitaros_sweden.shtml FDA accepts Sandoz application for biosimilar filgrastim http://www.sandoz.com/media_center/press_releases_news/global_news/2014_07_24_FDA_accepts_Sandoz_application_for_biosimilar_filgrastim.shtml Sandoz obtains rights in US to commercialize KERYDINTM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc. http://www.sandoz.com/media_center/press_releases_news/global_news/2014_07_21_Sandoz_obtains_rights_in_US_to_commercialize_KERYDINTM.shtml Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook http://www.sandoz.com/media_center/press_releases_news/global_news/2014_07_17_novartis_announces_q2_2014_results.shtml Sandoz launches authorized generic version of TOBI® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_07_15_Sandoz_launches_generic_TOBI.shtml Sandoz's Joerg Windisch Reelected as Chair of EGA’s European Biosimilars Group http://www.sandoz.com/media_center/press_releases_news/global_news/2014_07_09_Joerg_Windisch_Reelected_as_Chair_of_EGAs_European_Biosimilars_Group.shtml Sandoz launches authorized generic version of Diovan® in the US http://www.sandoz.com/media_center/press_releases_news/global_news/2014_07_08_Sandoz_launches_authorized_generic_of_Diovan_US.shtml Sandoz brings together key French stakeholders to discuss biosimilars http://www.sandoz.com/media_center/press_releases_news/global_news/2014_07_08_Sandoz_brings_together_key_French_stakeholders_to_discuss_biosimilars.shtml Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide http://www.sandoz.com/media_center/press_releases_news/global_news/2014_06_30_united_nations.shtml Sandoz launches Airflusal® Forspiro® in Sweden, further driving patient access to innovative new respiratory inhaler http://www.sandoz.com/media_center/press_releases_news/global_news/2014_06_23_Sandoz_launches_Airflusal_Forspiro_in_Sweden.shtml Sandoz launches three new products in Japan, including authorized generics of valsartan and zoledronic acid http://www.sandoz.com/media_center/press_releases_news/global_news/2014_06_20_Sandoz_launches_three_new_products_in_Japan.shtml GSK application for preliminary injunction withdrawn just before Cologne Court of appeals was to rule in the case http://www.sandoz.com/media_center/press_releases_news/global_news/2014_06_16_GSK_application_for_preliminary_injunction.shtml Sandoz launches generic version of key anti-depressant Cipralex® in several European countries http://www.sandoz.com/media_center/press_releases_news/global_news/2014_06_04_Sandoz_launches_generic_version_of_Cipralex.shtml Sandoz enhances strategic relationship with Upsher-Smith through marketing agreement for potassium chloride products http://www.sandoz.com/media_center/press_releases_news/global_news/2014_06_06_Sandoz_enhances_strategic_relationship_with_Upsher_Smith.shtml Sandoz France launches generic Nasonex® nasal spray, the first generic nasal corticoid on the French market http://www.sandoz.com/media_center/press_releases_news/global_news/2014_06_10_Sandoz_France_launches_generic_Nasonex.shtml Sandoz associates join Novartis Community Partnership Day 2014 http://www.sandoz.com/media_center/press_releases_news/global_news/2014_05_15_CPD.shtml Sandoz launches AirFluSal® Forspiro® in South Korea http://www.sandoz.com/media_center/press_releases_news/global_news/2014_05_14_Sandoz_launches_AirFluSal_Forspiro_in_South_Korea.shtml Court supports access to Sandoz’s innovative respiratory device in Norway http://www.sandoz.com/media_center/press_releases_news/global_news/2014_05_08_Court_support_access.shtml More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day http://www.sandoz.com/media_center/press_releases_news/global_news/2014_05_08_cpd_global_news.shtml SANDOZ ACHIEVES IMPORTANT MILESTONES ON PHASE III TRIALS FOR KEY BIOSIMILARS PROGRAMS http://www.sandoz.com/media_center/press_releases_news/global_news/2014_04_28_biosimilars_milestones.shtml Sandoz launches generic version of Differin® Gel, 0.3% http://www.sandoz.com/media_center/press_releases_news/global_news/2014_04_28_differin.shtml Novartis announces Q1 2014 results http://www.sandoz.com/media_center/press_releases_news/global_news/2014_04_24_novartis_announces_q1_2014_results.shtml Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics http://www.sandoz.com/media_center/press_releases_news/global_news/2014_04_22_Novartis_announces_portfolio_transformation_1.shtml Sandoz demonstrates innovation strength at “Long Night of Research“ http://www.sandoz.com/media_center/press_releases_news/global_news/2014_04_11_Lange_Nacht_der_Forschung.shtml Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz http://www.sandoz.com/media_center/press_releases_news/global_news/2014_04_09_Novartis_appoints_Jeff_George_as_Division.shtml Sandoz launches AirFluSal® Forspiro® in Norway http://www.sandoz.com/media_center/press_releases_news/global_news/2014_04_02_ariflusal_norway.shtml Sandoz launches first generic version of Taclonex® Ointment http://www.sandoz.com/media_center/press_releases_news/global_news/2014_04_02_taclonex.shtml Sandoz launches generic version of PREVPAC® in the US http://www.sandoz.com/media_center/press_releases_news/global_news/2014_03_31_prevpac.shtml Vas Narasimhan to lead Sandoz’ biosimilars business http://www.sandoz.com/media_center/press_releases_news/global_news/2014_03_27_Van_Narasimhan.shtml Sandoz receives approval for biosimilar filgrastim in Japan http://www.sandoz.com/media_center/press_releases_news/global_news/2014_03_24_Japan.shtml Tuberculosis remains a global health challenge; Sandoz continues commitment to fighting the disease http://www.sandoz.com/media_center/press_releases_news/global_news/2014_03_24_TB_article_3.shtml South Korea approves AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_02_28_South_Korea_approves_Sandoz_AirFluSal_Forspiro.shtml Jeff George speaks to Generics Bulletin about emerging markets http://www.sandoz.com/media_center/press_releases_news/global_news/2014_02_25_Jeff_George_speaks_to_Generics_Bulletin.shtml Belgium Approves Sandoz’S Airfusal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_02_11_Belgium_approves_Sandoz_AirFluSal_Forspiro.shtml Norway approves Sandoz’s AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_02_10_norway_approves_airflusal.shtml Sandoz launches the first generic version of Hectorol® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_02_06_Sandoz_launches_first_generic_version_of_Hectorol.shtml Bulgaria approves Sandoz’s AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_02_04_Bulgaria_approves_airflusal_forspiro.shtml Novartis announces Q4/Full Year 2013 results http://www.sandoz.com/media_center/press_releases_news/global_news/2014_01_29_novartis_announces_q4_2013_results.shtml Romania approves Sandoz’s AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_01_29_Romania_approves_airflusal_forspiro.shtml Sandoz launches AirFluSal ® Forspiro® in Denmark http://www.sandoz.com/media_center/press_releases_news/global_news/2014_01_20_Denmark_launches_airflusal_forspiro.shtml Hungary approves Sandoz’s AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_01_16_Hungary_approves_airflusal_forspiro.shtml Sweden approves Sandoz’s AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_01_14_Sweden_approves_airflusal_forspiro.shtml Germany approves Sandoz’s Airflusal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2014_01_13_Germany_approves_airflusal_forspiro.shtml Sandoz receives first approval for AirFluSal® Forspiro® http://www.sandoz.com/media_center/press_releases_news/global_news/2013_12_18_approval_airflusal_forspiro.shtml Sandoz begins Phase III clinical trial for biosimilar adalimumab http://www.sandoz.com/media_center/press_releases_news/global_news/2013_12_18_clinical_trial_for_biosimilar_adalimumab.shtml Sandoz B.V. and Novartis Confirm Receipt of a Decision from the European Commission http://www.sandoz.com/media_center/press_releases_news/global_news/2013_12_10_European_Comission.shtml Novartis Africa Day highlights company’s efforts to expand access to healthcare http://www.sandoz.com/media_center/press_releases_news/global_news/2013_12_05_nad.shtml Sandoz launches an authorized generic version of Solaraze® Gel http://www.sandoz.com/media_center/press_releases_news/global_news/2013_11_21_solarez_gel_1.shtml Sandoz Recognizes World Diabetes Day http://www.sandoz.com/media_center/press_releases_news/global_news/2013_11_14_world_diabetes_day.shtml Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety http://www.sandoz.com/media_center/press_releases_news/global_news/2013_10_30_novartis_group_fda_patient_safety.shtml Sandoz Applauds Governor Brown For Vetoing California Biosimilars Bill http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_applauds_governor_brown_for_vetoing_california_biosimilars_bill.shtml Sandoz recognizes International Day of Rural Women http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_recognizes_international_day_of_rural_women.shtml Sandoz’s Nick Haggar named new EGA president http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_s_nick_haggar_named_new_ega_president.shtml Sandoz launches an authorized generic of key oncology product VIDAZA® http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_an_authorized_generic_of_key_oncology_product_vidaza_reg_.shtml Sandoz launches SurePalTM – Simple and Secure Device Innovation for Patients Using Human Growth Hormone (hGH) http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_surepaltm_simple_and_secure_device_innovation_for_patients_using_human_growth_hormone_hgh_.shtml Sandoz supports tuberculosis awareness film in cooperation with Indian Ministry of Health http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_supports_tuberculosis_awareness_film_in_cooperation_with_indian_ministry_of_health.shtml Sandoz Canada launches Salinex ProTectTM http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_canada_launches_salinex_protecttm.shtml Sandoz launches Nexmezol, treatment for digestive disorders, in South Africa http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_nexmezol_treatment_for_digestive_disorders_in_south_africa.shtml Sandoz launches an authorized generic version of temozolomide capsules http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_an_authorized_generic_version_of_temozolomide_capsules.shtml Announcing re-launch of Sandoz-Biosimilars.com http://www.sandoz.com/media_center/press_releases_news/global_news/announcing_re-launch_of_sandoz-biosimilars_com_.shtml US FEDERAL CIRCUIT COURT OF APPEALS FINDS SANDOZ’S GENERIC COPAXONE® DOES NOT INFRINGE TEVA’S 2015 PATENT http://www.sandoz.com/media_center/press_releases_news/global_news/us_federal_circuit_court_of_appeals_finds_sandoz_rsquo_s_generic_copaxone_reg_does_not_infringe_teva_rsquo_s_2015_patent.shtml CHMP Positive Opinion on Methylphenidate http://www.sandoz.com/media_center/press_releases_news/global_news/chmp_positive_opinion_on_methylphenidate.shtml NEW EPISODE OF SANDOZ TV AVAILABLE http://www.sandoz.com/media_center/press_releases_news/global_news/new_episode_of_sandoz_tv_available.shtml NEW EPISODE OF SANDOZ TV AVAILABLE http://www.sandoz.com/media_center/press_releases_news/global_news/new_episode_of_sandoz_tv_available.shtml Sandoz’s Nick Haggar speaks to Generics Bulletin http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_rsquo_s_nick_haggar_speaks_to_generics_bulletin.shtml SANDOZ’S AMEET MALLIK SPEAKS TO GENERICS BULLETIN http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_rsquo_s_ameet_mallik_speaks_to_generics_bulletin.shtml ZARZIO® OVERTAKES NEUPOGEN® AND GRANOCYTE® TO BECOME MOST PRESCRIBED DAILY G-CSF IN EUROPE http://www.sandoz.com/media_center/press_releases_news/global_news/zarzio_reg_overtakes_neupogen_reg_and_granocyte_reg_to_become_most_prescribed_daily_g-csf_in_europe_.shtml Sandoz’s Helmut Fabry speaks to Generics Bulletin http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_rsquo_s_helmut_fabry_speaks_to_generics_bulletin.shtml Novartis announces its second quarter and half year results for 2013 today. http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_its_second_quarter_and_half_year_results_for_2013_today_.shtml Sandoz launches first generic version of METROGEL® 1% in the US http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_first_generic_version_of_metrogel_reg_1_in_the_us.shtml Sandoz launches Phase III clinical trial for biosimilar etanercept http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_phase_iii_clinical_trial_for_biosimilar_etanercept.shtml Sandoz launches generic version of BENET® Tablets / ACTONEL® Tab in Japan http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_generic_version_of_benet_reg_tablets_actonel_reg_tab_in_japan.shtml Sandoz responds to EMA Draft Revision of Biosimilar Development Guidelines http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_responds_to_ema_draft_revision_of_biosimilar_development_guidelines.shtml FACTS & FIGURES 2012 NOW AVAILABLE http://www.sandoz.com/media_center/press_releases_news/global_news/facts_amp_figures_2012_now_available.shtml Sandoz responds to FDA warning letter http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_responds_to_fda_warning_letter.shtml Sandoz launches first generic version of ATACAND® http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_first_generic_version_of_atacand_reg_.shtml Novartis wins GBCHealth Business Action on Health Award for social ventures initiative http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_wins_gbchealth_business_action_on_health_award_for_social_ventures_initiative.shtml New episode of Sandoz TV available http://www.sandoz.com/media_center/press_releases_news/global_news/new_episode_of_sandoz_tv_available.shtml Celebrating Novartis’ 17th Community Partnership Day http://www.sandoz.com/media_center/press_releases_news/global_news/celebrating_novartis_17th_community_partnership_day_.shtml Sandoz Files for Marketing Authorization of Biosimilar Filgrastim in Japan http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_files_for_marketing_authorization_of_biosimilar_filgrastim_in_japan.shtml Novartis announces Q1 2013 results http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q1_2013_results.shtml Sandoz’ Mark McCamish ranked 12th most influential person in antibody industry http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_rsquo_mark_mccamish_ranked_12th_most_influential_person_in_antibody_industry.shtml Sandoz strengthens oral contraceptive portfolio by launching generic versions of Ortho Cyclen® and Ortho Tri-Cyclen® http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_strengthens_oral_contraceptive_portfolio_by_launching_generic_versions_of_ortho_cyclen_reg_and_ortho_tri-cyclen_reg_.shtml Sandoz expands Kundl site sterile production http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_expands_kundl_site_sterile_production_.shtml Sandoz launches an authorized generic version of argatroban injection (aqueous solution for intravenous infusion) http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_an_authorized_generic_version_of_argatroban_injection_aqueous_solution_for_intravenous_infusion_.shtml Sandoz launches first generic version of Cleocin Phosphate® in Dextrose 5% http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_first_generic_version_of_cleocin_phosphate_reg_in_dextrose_5_.shtml Sandoz and Novartis confirm receipt of EU Statement of Objection http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_and_novartis_confirm_receipt_of_eu_statement_of_objection.shtml NEW EPISODE OF SANDOZ TV AVAILABLE http://www.sandoz.com/media_center/press_releases_news/global_news/new_episode_of_sandoz_tv_available.shtml NOVARTIS ANNOUNCES Q4/FULL YEAR 2012 RESULTS http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q4_full_year_2012_results.shtml Sandoz launches first generic version of DUETACT® http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_first_generic_version_of_duetact_reg_.shtml The first Bioequivalence Center in East Africa is launched with support from Sandoz http://www.sandoz.com/media_center/press_releases_news/global_news/the_first_bioequivalence_center_in_east_africa_is_launched_with_support_from_sandoz.shtml Sandoz begins phase III studies in the United States for biosimilar epoetin alfa http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_begins_phase_iii_studies_in_the_united_states_for_biosimilar_epoetin_alfa.shtml Novartis announces Q3 2012 results http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q3_2012_results.shtml Sandoz strengthens leadership in generic dermatology with launch of generic version of TOPICORT® 0.25% Ointment http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_strengthens_leadership_in_generic_dermatology_with_launch_of_generic_version_of_topicort_reg_0_25_ointment_.shtml Novartis Group maximizes patient access and choice with launch of Sandoz authorized generic Diovan HCT® in the US http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_group_maximizes_patient_access_and_choice_with_launch_of_sandoz_authorized_generic_diovan_hct_reg_in_the_us.shtml Sandoz strengthens US respiratory portfolio with launch of generic version of SINGULAIR® http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_strengthens_us_respiratory_portfolio_with_launch_of_generic_version_of_singulair_reg_.shtml Sandoz launches first-to-file calcipotriene cream, the first generic version of Dovonex® http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_first-to-file_calcipotriene_cream_the_first_generic_version_of_dovonex_reg_.shtml Sandoz completes acquisition of Fougera Pharmaceuticals, positioning Sandoz as #1 in generic dermatology globally http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_completes_acquisition_of_fougera_pharmaceuticals_positioning_sandoz_as_1_in_generic_dermatology_globally_.shtml Novartis announces Q2 2012 results http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q2_2012_results.shtml New study shows biosimilars can save healthcare systems of eight EU countries up to EUR 33 billion by 2020 http://www.sandoz.com/media_center/press_releases_news/global_news/new_study_shows_biosimilars_can_save_healthcare_systems_of_eight_eu_countries_up_to_eur_33_billion_by_2020.shtml New episode of Sandoz TV available http://www.sandoz.com/media_center/press_releases_news/global_news/new_episode_of_sandoz_tv_available.shtml Sandoz testimony at FDA hearing on biosimilars will emphasize need for consistent regulatory standards across all biologics http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_testimony_at_fda_hearing_on_biosimilars_will_emphasize_need_for_consistent_regulatory_standards_across_all_biologics.shtml Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_to_acquire_fougera_pharmaceuticals_becoming_the_number_one_generic_dermatology_medicines_company_globally_and_in_the_us.shtml Novartis announces Q1 2012 results http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q1_2012_results.shtml AVAILABLE NOW! NEW EPISODE OF SANDOZ TV http://www.sandoz.com/media_center/press_releases_news/global_news/available_now_new_episode_of_sandoz_tv_.shtml Novartis announces Q4/Full Year 2011 results http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q4_full_year_2011_results.shtml Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_initiates_two_more_phase_iii_biosimilar_trials_reinforcing_long-term_global_leadership_commitment_.shtml NEW EPISODE OF SANDOZ TV NOW AVAILABLE! http://www.sandoz.com/media_center/press_releases_news/global_news/new_episode_of_sandoz_tv_now_available_.shtml NOVARTIS ANNOUNCES Q3 2011 RESULTS http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q3_2011_results.shtml SANDOZ HEAD JEFF GEORGE NAMED TOP "40 UNDER 40" http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_head_jeff_george_named_top_40_under_40_.shtml NOVARTIS ANNOUNCES Q2 2011 RESULTS http://www.sandoz.com/media_center/press_releases_news/global_news/global_news/novartis_announces_q2_2011_results.shtml NOVARTIS ANNOUNCES Q1 2011 RESULTS http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q1_2011_results.shtml NOVARTIS ANNOUNCES Q4/FULL YEAR 2010 RESULTS http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_announces_q4_full_year_2010_results.shtml SANDOZ ANNOUNCES PHASE II CLINICAL TRIAL FOR BIOSIMILAR VERSION OF LEADING MONOCLONAL ANTIBODY RITUXIMAB http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_announces_phase_ii_clinical_trial_for_biosimilar_version_of_leading_monoclonal_antibody_rituximab.shtml GLOBAL BIOSIMILAR LEADER SANDOZ TESTIFIES FOR NOVARTIS AT FDA HEARING ON US BIOSIMILAR PATHWAY http://www.sandoz.com/media_center/press_releases_news/global_news/global_biosimilar_leader_sandoz_testifies_for_novartis_at_fda_hearing_on_us_biosimilar_pathway.shtml SANDOZ ONCOLOGY INJECTABLES BUSINESS POSITIONED FOR GLOBAL LEADERSHIP http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_oncology_injectables_business_positioned_for_global_leadership.shtml SANDOZ LEADS THE WAY WITH FIRST GENERIC VERSION OF 'GOLD STANDARD' ANTI-THROMBOTIC LOVENOX®[1] http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_leads_the_way_with_first_generic_version_of_gold_standard_anti-thrombotic_lovenox_reg_1_.shtml NOVARTIS DELIVERS STRONG FINANCIAL PERFORMANCE IN SECOND QUARTER, UNDERPINNED BY INCREASED MOMENTUM IN INNOVATION http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_delivers_strong_financial_performance_in_second_quarter_underpinned_by_increased_momentum_in_innovation.shtml NICE ISSUES FIRST BIOSIMILAR RECOMMENDATION, SAYING OMNITROPE® OFFERS SAME EFFICACY AND SAFETY AS OTHER SOMATROPINS http://www.sandoz.com/media_center/press_releases_news/global_news/nice_issues_first_biosimilar_recommendation_saying_omnitrope_reg_offers_same_efficacy_and_safety_as_other_somatropins.shtml NOVARTIS QUARTERLY RESULTS Q1 2010 http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_quarterly_results_q1_2010.shtml SANDOZ TO ACQUIRE ORIEL THERAPEUTICS, GAINING RIGHTS TO PORTFOLIO OF RESPIRATORY PRODUCTS TARGETING ASTHMA AND COPD http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_to_acquire_oriel_therapeutics_gaining_rights_to_portfolio_of_respiratory_products_targeting_asthma_and_copd_.shtml SANDOZ STATEMENT ON PASSAGE OF US BIOSIMILARS PATHWAY LEGISLATION http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_statement_on_passage_of_us_biosimilars_pathway_legislation.shtml Latest Results - Full Year/Q4 2009 http://www.sandoz.com/media_center/press_releases_news/global_news/latest_results_-_full_year_q4_2009.shtml NOVARTIS Q3 2010 RESULTS http://www.sandoz.com/media_center/press_releases_news/global_news/novartis_q3_2010_results.shtml SANDOZ COMPLETES ACQUISITION OF EBEWE PHARMA, IMPROVING GLOBAL PATIENT ACCESS TO AFFORDABLE INJECTABLE CANCER MEDICINES http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_completes_acquisition_of_ebewe_pharma_improving_global_patient_access_to_affordable_injectable_cancer_medicines.shtml SANDOZ LAUNCHES FIRST GENERIC VERSION OF PROGRAF® CAPSULES http://www.sandoz.com/media_center/press_releases_news/global_news/sandoz_launches_first_generic_version_of_prograf_reg_capsules.shtml MAJOR INVESTMENT http://www.sandoz.com/media_center/press_releases_news/global_news/major_investment.shtml NEW ECONOMIC STUDY http://www.sandoz.com/media_center/press_releases_news/global_news/new_economic_study.shtml LATEST RESULTS - SECOND QUARTER AND FIRST HALF 2009 http://www.sandoz.com/media_center/press_releases_news/global_news/latest_results_-_second_quarter_and_first_half_2009.shtml